Mustang Bio, Inc. (MBIO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean...
All 23 treated patients are alive at 2.6-year median follow-up without evidence of malignant transformation Data representing largest cohort of infants...
Data from two programs selected for oral presentations at the upcoming American Society of Gene & Cell Therapy 25th Annual Meeting and the European...
Favorable safety profile, high overall response and complete response rates, and CAR T persistence observed in patients with relapsed or refractory...
Data represent largest cohort of infants with XSCID, also known as bubble boy disease, who received lentiviral gene therapy with the longest follow-up to...
Fred Hutch’s Dr. Mazyar Shadman to present data on Mustang’s autologous CAR T-cell therapy for the treatment of B-cell non-Hodgkin lymphomas and chronic...
MB‐101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) are well tolerated in patients with recurrent GBM in ongoing Phase 1...
WORCESTER, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on...
WORCESTER, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on...
WORCHESTER, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on...